Raymond James & Associates’s Standard BioTools LAB Stock Holding History

Raymond James & Associates’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18,194	Closed	-$32.2K	–	4057
2024 Q2	$32.2K	Hold	18,194	–	–	﹤0.01%	3841
2024 Q1	$49.3K	Buy	+18,194	New	+$43.9K	﹤0.01%	3803
2015 Q4	–	Sell	-44,603	Closed	-$362K	–	2368
2015 Q3	$362K	Sell	44,603 -12,451	-22%	-$196K	﹤0.01%	2066
2015 Q2	$1.38M	Buy	57,054 +2,408	+4%	+$76K	0.01%	1553
2015 Q1	$2.3M	Sell	54,646 -4,981	-8%	-$197K	0.01%	1163
2014 Q4	$2.01M	Buy	59,627 +16,981	+40%	+$481K	0.01%	1153
2014 Q3	$1.04M	Buy	42,646 +2,374	+6%	+$66.7K	0.01%	1472
2014 Q2	$1.18M	Buy	+40,272	New	+$1.29M	0.01%	1398

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's LAB Position: Q3 2024 in Review

Raymond James & Associates sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 18,194 shares — an estimated $32.2K sold.

Raymond James & Associates first reported a position in LAB in Q2 2014 and held it in 8 quarters. The position peaked at $2.3M in Q1 2015. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

Raymond James & Associates reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
Raymond James & Associates sold 18,194 Standard BioTools shares in Q3 2024, an estimated $32.2K.
Raymond James & Associates first reported a position in Standard BioTools in Q2 2014 and held it in 8 quarters.
Raymond James & Associates's Standard BioTools position peaked at $2.3M in Q1 2015.
141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.